Drug Doses & Preparation | Complete professional monograph and nursing note sheet
Generic: Ondansetron hydrochloride injection, a 5-HT3 receptor antagonist. This article focuses on the cited 2 mg/mL US injection label for prevention of chemotherapy-associated and postoperative nausea/vomiting. Other indications and Indian product inserts may differ.
Ondansetron quick note sheet
- Injection: 4 mg/2 mL = 2 mg/mL in the cited single-dose vial.
- Chemotherapy-associated nausea/vomiting: 0.15 mg/kg IV per dose for three doses, maximum 16 mg per dose, in adults and children at least 6 months old; first dose before chemotherapy, subsequent doses 4 and 8 hours later.
- Chemotherapy IV preparation: dilution in 50 mL of 0.9% sodium chloride or 5% dextrose required for the cited label; infuse over 15 minutes.
- Postoperative nausea/vomiting: separate indication-specific dose and administration instructions; dilution is not required for the cited injection label.
- Severe hepatic impairment: do not exceed 8 mg total daily dose.
- High-alert checks: QT prolongation, hypokalemia/hypomagnesemia, congenital long-QT syndrome, serotonergic drugs and apomorphine contraindication.
Clinical role
Ondansetron injection is approved in the cited label for prevention of nausea/vomiting associated with emetogenic chemotherapy and postoperative nausea/vomiting. It is not an automatic treatment for every undifferentiated vomiting presentation; assess dehydration, obstruction, metabolic causes and other red flags.
Dosage forms and strengths
| Form | Example | Safety point |
|---|---|---|
| Injection, single-dose vial | 4 mg/2 mL (2 mg/mL) | Confirm vial label and preservative status |
| Other injectable presentations | Market-dependent | Do not assume 2 mg/mL |
| Oral tablets/ODT/solution | Product-specific | Not interchangeable with IV preparation instructions |
Indian availability: injectable ondansetron is used in India, but no brand photograph or manufacturer-specific pack is asserted here without current verification. Read the actual Indian pack and approved insert.
Adult and paediatric dose by indication
| Indication | Label-based dose | Timing and route |
|---|---|---|
| Emetogenic chemotherapy, adults and children ≥6 months | 0.15 mg/kg per dose; maximum 16 mg per dose; 3 doses | 15-minute IV infusion; first 30 minutes before chemotherapy; subsequent doses at 4 and 8 hours after first |
| Postoperative nausea/vomiting, adults | 4 mg IV or IM once | IV undiluted slowly according to product label, preferably over 2–5 minutes; or IM |
| Postoperative nausea/vomiting, paediatric patients | Weight- and age-dependent: for patients ≤40 kg, 0.1 mg/kg IV; above 40 kg, 4 mg IV in the cited label | Use only when patient meets the label’s age/clinical criteria and follow the exact injection label |
| Severe hepatic impairment | Maximum total 8 mg/day | Review Child-Pugh status and all doses |
Neonates and young infants: do not extrapolate chemotherapy dosing to children younger than 6 months. The cited postoperative label covers patients at least 1 month old; specialist assessment is required.
Nursing preparation: chemotherapy-associated nausea/vomiting
- Verify patient, chemotherapy regimen, indication, weight, order, age, QT risk, serum potassium/magnesium and hepatic function.
- Read the exact ampoule/vial concentration. The cited vial is 2 mg/mL.
- Calculate ordered dose in mg, respecting the label maximum. Then calculate withdrawal volume = mg ÷ 2 mg/mL.
- Use aseptic technique and withdraw the calculated volume.
- For the cited chemotherapy indication, dilute in 50 mL 0.9% sodium chloride or 5% dextrose. For infants 6–12 months and/or patients weighing ≤10 kg, the cited label permits 10–50 mL depending on fluid requirements.
- Infuse over 15 minutes. Check final total volume, pump setting and local pharmacy protocol.
- Inspect for particulate matter/discoloration. Do not mix with unverified drugs or alkaline solutions; use the manufacturer-specific stability and beyond-use information.
Worked calculation examples — arithmetic only
Adult example: A prescribed 8 mg chemotherapy dose with a verified 2 mg/mL vial requires 4 mL withdrawal. If final infusion volume is 54 mL (50 mL diluent plus 4 mL drug, with no volume removed), the pump rate over 15 minutes is 216 mL/hour. If pharmacy prepares an exact final volume of 50 mL instead, the rate is 200 mL/hour. Always program the actual measured final volume, not an assumed bag size.
Paediatric example: 20 kg × 0.15 mg/kg = 3 mg. At 2 mg/mL, withdrawal volume = 1.5 mL. If pharmacy prepares an exact final volume of 50 mL, a 15-minute infusion rate is 200 mL/hour. Confirm the prescribed indication and actual final volume; this example is not an order.
Postoperative administration
For the cited label, dilution is not required for postoperative use. Adults commonly receive 4 mg IV or IM. For IV administration, follow the current label’s slow-injection directions and do not apply the chemotherapy dilution instructions automatically. Paediatric postoperative dosing must follow age/weight criteria and anesthesia protocol.
Storage, stability and compatibility
Use the actual manufacturer label for storage, light protection, container entry and beyond-use times. Compatible infusion diluents for the cited chemotherapy preparation include 0.9% sodium chloride and 5% dextrose. Do not mix with alkaline or unverified solutions; a product-specific compatibility table is required for Y-site use.
Renal and hepatic considerations
Severe hepatic impairment requires an 8 mg/day ceiling in the cited label. Routine renal adjustment is generally not required by the cited prescribing information, but severe illness and other medications require review.
Pregnancy and lactation
Use only when clinically indicated after reviewing current pregnancy safety evidence, fetal risk considerations and local obstetric guidance. Lactation decisions should consider infant condition and up-to-date product information; do not assume an IV oncology regimen is appropriate for pregnancy-related nausea.
Contraindications, interactions and adverse effects
- Contraindications: hypersensitivity and concomitant apomorphine use.
- Cardiac: dose-related QT prolongation and torsades risk; avoid in congenital long-QT syndrome, correct electrolyte disturbances and review QT-prolonging medicines.
- Serotonergic medicines: assess serotonin syndrome risk.
- Common adverse effects: headache, constipation and injection-site reactions; other reactions depend on indication and patient population.
- Postoperative: ondansetron may mask progressive ileus or gastric distention.
Monitoring checklist
- Indication and clinical response
- ECG/QT risk, potassium and magnesium when clinically indicated
- Medication reconciliation including apomorphine, serotonergic and QT-prolonging medicines
- Hepatic function, prescribed daily total and age/weight
- Infusion line, preparation label, administered dose and pump rate
What is known and limitations
The chemotherapy preparation and 15-minute infusion, postoperative undiluted administration, 2 mg/mL formulation and severe-hepatic-impairment limit are supported by the cited official label. India-specific brands, exact local product stability and off-label gastroenteritis or pregnancy regimens are not established by this article. Use local approved labels and protocols.
Primary sources
- DailyMed: Ondansetron Injection official prescribing information
- DailyMed: Ondansetron Injection detailed preparation information
Last reviewed: 11 October 2026
Medical disclaimer: Professional educational reference only. Verify patient-specific prescription, formulation, age, dose, diluent, final volume, infusion rate, QT risk and local protocol before administration.